Diane D Lu1, Stephen A Boorjian2, Jay D Raman3. 1. Division of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA. 2. Department of Urology, Mayo Clinic-Minnesota, Rochester, MN. 3. Division of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA. Electronic address: jraman@hmc.psu.edu.
Abstract
To determine the use of prophylactic intravesical chemotherapy (pIVC) following radical nephroureterectomy (RNU) and barriers to utilization in a survey study of urologic oncologists. METHODS: A survey instrument was constructed, which queried respondents on professional experience, practice environment, pIVC use, and reasons for not recommending pIVC when applicable. The survey was electronically distributed to members of the Society of Urologic Oncology over an 8-week period. Survey software was used for analysis. RESULTS: The survey response rate was 22% (158 of 722). Half of the respondents were in practice for ≤10 years, while 90% performed ≤10 RNU cases annually. Of the 144 urologists regularly performing RNU, only 51% reported administering pIVC, including 22 exclusively in patients with a prior history of bladder cancer. One-third administered pIVC intraoperatively, whereas the remainder instilled pIVC at ≤3 (7%), 4 to 7 (37%), 8 to 14 (20%), and>14 (3%) days postoperatively. Almost all urologists noted giving a single instillation of pIVC. Agents included mitomycin-C (88%), thiotepa (7%), doxorubicin (3%), epirubicin (1%), and BCG (1%). Among respondents who did not administer pIVC, the most common reasons cited included lack of data supporting use (44%), personal preference (19%), and office infrastructure (17%). CONCLUSION: Only 51% of urologic oncologists report using pIVC in patients undergoing RNU. Reasons underlying this underutilization are multifactorial, thereby underscoring the need for continued dissemination of existing data and additional studies to support its benefits. Moreover, improving the logistics of pIVC administration may help to increase utilization rates.
To determine the use of prophylactic intravesical chemotherapy (pIVC) following radical nephroureterectomy (RNU) and barriers to utilization in a survey study of urologic oncologists. METHODS: A survey instrument was constructed, which queried respondents on professional experience, practice environment, pIVC use, and reasons for not recommending pIVC when applicable. The survey was electronically distributed to members of the Society of Urologic Oncology over an 8-week period. Survey software was used for analysis. RESULTS: The survey response rate was 22% (158 of 722). Half of the respondents were in practice for ≤10 years, while 90% performed ≤10 RNU cases annually. Of the 144 urologists regularly performing RNU, only 51% reported administering pIVC, including 22 exclusively in patients with a prior history of bladder cancer. One-third administered pIVC intraoperatively, whereas the remainder instilled pIVC at ≤3 (7%), 4 to 7 (37%), 8 to 14 (20%), and>14 (3%) days postoperatively. Almost all urologists noted giving a single instillation of pIVC. Agents included mitomycin-C (88%), thiotepa (7%), doxorubicin (3%), epirubicin (1%), and BCG (1%). Among respondents who did not administer pIVC, the most common reasons cited included lack of data supporting use (44%), personal preference (19%), and office infrastructure (17%). CONCLUSION: Only 51% of urologic oncologists report using pIVC in patients undergoing RNU. Reasons underlying this underutilization are multifactorial, thereby underscoring the need for continued dissemination of existing data and additional studies to support its benefits. Moreover, improving the logistics of pIVC administration may help to increase utilization rates.
Authors: Mounsif Azizi; Salim K Cheriyan; Charles C Peyton; Beat Foerster; Shahrokh F Shariat; Philippe E Spiess Journal: Curr Treat Options Oncol Date: 2019-04-01
Authors: Clint Cary; Yan Tong; Susan Linsell; Khurshid Ghani; David C Miller; Michael Weiner; Michael O Koch; Susan M Perkins; Gregory Zimet Journal: J Urol Date: 2021-09-23 Impact factor: 7.450
Authors: Eu Chang Hwang; Niranjan J Sathianathen; Jae Hung Jung; Myung Ha Kim; Philipp Dahm; Michael C Risk Journal: Cochrane Database Syst Rev Date: 2019-05-18
Authors: Tom-Régis Dobé; Gianluigi Califano; Friedrich-Carl von Rundstedt; Idir Ouzaid; Simone Albisinni; Atiqullah Aziz; Ettore Di Trapani; Kees Hendricksen; Wojciech Krajewski; Andrea Mari; Marco Moschini; Andrea Necchi; Aidan P Noon; Cedric Poyet; Benjamin Pradère; Michael Rink; Florian Roghmann; Paul Sargos; Roland Seiler; Francesco Soria; Malte W Vetterlein; Evanguelos Xylinas Journal: Eur Urol Open Sci Date: 2020-11-06